French medical imaging start-up, Therapixel, has raised €15m in a series B funding round led by Crédit Mutuel Innovation and CapHorn, with participation from Verve, SHAM Innovation Santé, and existing investors Omnes, IT-Translation/Elaia, M-Capital and Région Sud Investissement. Therapixel's artificial intelligence technology improves the reading of mammograms to help radiologists detect anomalies that may be missed. The funding will enable the company to accelerate its commercial deployment in the United States, launch new unique functionalities for MammoScreen and push the technical limits of its intelligent mammography reading solution even further.
Founded in 2013 by two computer scientists from Inria, Pierre Fillard and Olivier Clatz, Therapixel has developed an AI technology that improves the reading of mammograms by drawing the expert eye of radiologists to anomalies that may be missed. The company's flagship product, MammoScreen, has been approved for use in Europe by the European Union and is in the process of being approved for use in the United States by the FDA.
Crédit Mutuel Innovation is a venture capital firm that invests in innovative start-ups in the technology, healthcare and digital sectors. CapHorn is a French venture capital firm that invests in early-stage companies in the technology and digital sectors. Verve is a venture capital firm that invests in early-stage companies in the healthcare and life sciences sectors. SHAM Innovation Santé is an innovation incubator created by SHAM, a French insurance company that specializes in risk management for the healthcare sector. Omnes is a European venture capital firm that invests in start-ups in the technology, healthcare, and energy sectors. IT-Translation/Elaia is a French venture capital firm that invests in early-stage companies in the technology and digital sectors. M-Capital is a venture capital firm that invests in early-stage companies in the healthcare and life sciences sectors. Région Sud Investissement is a regional investment fund that invests in companies located in the Provence-Alpes-Côte d'Azur region of France.
In conclusion, Therapixel's latest funding round will allow the company to continue developing its innovative AI technology for mammography reading and expand its commercial reach in the United States. The involvement of several notable venture capital firms and insurance companies in this funding round demonstrates the potential for Therapixel's technology to disrupt the medical imaging industry.
